Relypsa (RLYP) Short Report 'Built on Unreliable Safety Data' - Feuerstein
Tweet
Share
E-mail.jpg)
Get Alerts RLYP Hot Sheet
Price: $31.99 --0%
Rating Summary:
3 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
3 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
Relypsa (NASDAQ: RLYP) is on watch following a report from TheStreet's Adam Feuerstein that the new bearish report from Elliot Favus was built on unreliable safety data as he is "trying to bail out his clients"
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
- Boston Beer Company (SAM) PT Lowered to $325 at Jefferies
- Tesla (TSLA) soars on Q1 print
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkRelated Entities
Adam FeuersteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
